A study in the Journal of Pediatrics reports that infants and toddlers are less likely to contract flu, pneumonia or influenza like illnesses, if given two doses of the influenza vaccine.
The American Cancer Society in its journal CA: A Cancer Journal for Clinicians recommended that girls ages 11 and 12 receive Merck’s human papillomavirus vaccine Gardasil.
University of South Florida researchers report that a novel needle-free vaccine approach is effective and safe in clearing brain-damaging plaques from a mouse model of Alzheimer’s disease.
A new study by researchers at the Harvard School of Public Health (HSPH) finds that polio vaccination in the United States has resulted in a net savings of over $180 billion.
The United Nations health agency outlined its ambitious goals of expanding the integrated delivery of immunization and preventive treatment against a whole host of diseases.
A new study by researchers at the Harvard School of Public Health (HSPH) finds that polio vaccination in the United States has resulted in a net savings of over $180 billion, even without including the large, intangible benefits associated with avoided fear and suffering.
A national report released shows that Minnesota ranks first in the nation in its efforts against cervical cancer, receiving the report’s first-ever “Excellent” grade, but there is still room to improve. According to the third annual report, “Partnering for Progress 2007: the ‘State’ of Cervical Cancer Prevention in America,” issued by Women In Government, Minnesota scored 83% out of a possible 100%. Last year, the state received a grade of “Very Good” and a score of 81%.
The Kentucky bill would require girls in public and private middle schools to get the Gardasil cervical cancer vaccine, which is aimed at four strains of the sexually transmitted human papillomavirus, also known as HPV. Two of the strains cause about 70 percent of cervical cancer cases.
New Hampshire’s health department will send its first shipments of a new vaccine that prevents cervical cancer to doctors this week. But many local practices say that the amount being sent won’t be enough to meet the demand for an unusually popular vaccine.
In a move that promises to expand the types of malaria vaccine candidates in clinical development, the PATH Malaria Vaccine Initiative today announced a new partnership with Sanaria Inc., a Maryland company, to accelerate development of a unique malaria vaccine candidate.